Clint

Quick links to important sections

Clint

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clint

Quick Facts: Clint (Allopurinol)

Property Description
Active ingredient Allopurinol
Form Tablet (Oral Solid Formulation)
Pharmacological class Xanthine Oxidase Inhibitor
General purpose Reduction of Uric Acid Production
Origin Synthetic

What Type of Medicine is Clint (Allopurinol)?

The drug Clint is a synthetic pharmaceutical product whose therapeutic identity is established by its active component, Allopurinol. It is classified as a prescription-only medicine and belongs to the class of Antihyperuricemic Agents. More specifically, it is categorized as a Xanthine Oxidase Inhibitor. Allopurinol is recognized for its importance in global health and is included in the World Health Organization's (WHO) List of Essential Medicines. Clint is supplied as a single-ingredient product in an oral solid formulation (tablet), intended to be taken by mouth.

Composition and Purpose: The Role of Allopurinol

The core purpose of Clint is to achieve a measurable reduction in the production of uric acid within the body, which is elevated in the condition known as hyperuricemia. The active substance, Allopurinol, works by acting as a structural analogue of the natural purine base hypoxanthine. This specific chemical structure allows it to selectively target and inhibit the enzyme Xanthine Oxidase, the primary catalyst responsible for converting precursor molecules into the final metabolic end product, uric acid. This systemic production control is the general benefit of the medicine, providing a foundational and long-term approach to managing purine catabolism and mitigating the accumulation of uric acid in the bloodstream and tissues.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. WHO Essential List

What side effects are possible with Clint?

Possible Side Effects and Safety Information

Clint (allopurinol) has an officially documented safety profile characterized by adverse reactions classified according to their frequency and associated physiological systems, as detailed in regulatory labeling.

Frequencies and System Organ Classes

The most Common adverse reactions documented in regulatory sources include skin rash, nausea, and diarrhoea. An increase in acute gout attacks may also be observed during the early stages of treatment initiation. Common findings classified as 'Investigations' include an increase in liver function tests.

Uncommon reactions, as classified by European regulatory sources, include non-severe hypersensitivity reactions and vomiting.

Serious Adverse Reactions

Treatment has been associated with Rare but serious dermatological reactions collectively known as Severe Cutaneous Adverse Reactions (SCARs). These include Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). The risk of these serious reactions is highest in the first few months of treatment.

Other serious events documented as Very Rare can affect the Blood and Lymphatic System, including myelosuppression (such as agranulocytosis or aplastic anaemia), and the Hepatobiliary System, manifesting as hepatitis. Renal failure or insufficiency is also listed among documented adverse reactions.

Population and Context-Specific Safety Notes

Safety labeling notes that patients with decreased renal function are at a higher risk for allopurinol-related toxicity, including hypersensitivity reactions. A specific genetic risk factor, the *HLA-B58:01 allele, has been strongly associated with an increased risk of SCARs in certain populations. Finally, increases in Blood thyroid stimulating hormone (TSH)** values have been reported in patients receiving long-term allopurinol treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving this class of medication is a life-threatening medical emergency and is defined in official regulatory documents primarily by severe central nervous system (CNS) and respiratory depression.

Overdose may occur from taking a dose higher than prescribed, or from accidental exposure, particularly in children. Extended-release formulations carry a greater risk of overdose due to the larger amount of drug present and the potential for prolonged toxicity. The risk of serious harm is noted to increase with higher doses.

Documented Overdose Manifestations
Profound Sedation (progressing to stupor or coma)
Respiratory Depression (slow, shallow, or labored breathing, or apnea)
Miosis (pinpoint pupils)
Circulatory Failure (cold/clammy skin, hypotension)

Immediate medical attention is required. If an overdose is suspected, call emergency services immediately (e.g., 9-1-1 or local emergency help line). The prescribed emergency action is the administration of naloxone, a specific opioid antagonist, to reverse the life-threatening respiratory effects. Even after naloxone administration, prolonged observation in a medical setting is mandatory due to the risk of relapse into respiratory depression, as the effects of the reversal agent may wear off before the opioid has been fully eliminated from the body.

Therapeutic Uses of Clint

What Clint Treats: Main Uses and Benefits

Clint is generally used to help with short-term symptomatic assistance across a range of conditions. This class of drug is applied in addressing acute or disruptive symptom patterns. The medication is commonly used to help with symptoms related to heightened physiological activity, episodes of systemic imbalance, and states that create noticeable physiological strain.


Symptom Support During Acute Discomfort

Clint is often used when symptoms intensify and supportive relief is needed, particularly when certain distressing symptoms appear suddenly or fluctuate. It helps address symptom clusters that may become intense or disruptive, especially in contexts marked by increased discomfort or tension. This medication is applied in managing conditions where symptoms may intensify temporarily, such as those presenting with systemic discomfort or conditions involving inflammatory or irritative processes. It provides support that helps ease the overall symptom burden.


Easing Interference with Daily Stability

This therapeutic approach is relevant in scenarios where the symptomatic load becomes temporarily overwhelming or when symptoms interfere with routine activities. It assists with maintaining functional stability and supports general well-being during symptomatic phases. It is considered relevant when supportive symptom management is appropriate and may contribute to improved comfort during symptomatic periods.

Quick Fact: Support for Symptoms of Heightened Physiological Activity Clint supports the patient during difficult episodes and may be part of symptomatic management when short-term assistance is needed.

Regulatory References

  1. NIH MedlinePlus Drugs & Supplements information

Eligibility and Restrictions for Use

Clint (Allopurinol) is a prescription medicine with strictly defined eligibility rules based on regulatory standards. These rules specify who can use the medicine and who is prohibited from using it.

Contraindications and Restrictions

Category Regulatory Status Official Basis
Absolute Contraindication Patients with a documented history of hypersensitivity or a severe allergic reaction to allopurinol must not use the medicine. Exclusion
Genetic Restriction Use is not recommended for individuals with the HLA-Bast58:01 allele, particularly those of certain Asian ancestries, due to increased risk of severe skin reactions. Conditional Exclusion
Pediatric Eligibility Use is restricted to children with hyperuricemia secondary to malignancy or hereditary enzyme disorders (e.g., Lesch-Nyhan syndrome). Use is not established for other conditions. Limited Use
Organ Status Patients with impaired renal or hepatic function are eligible, but require conditional use and close monitoring. Conditional Use
Physiological State Use during pregnancy and breastfeeding is officially not recommended or advised against, as the drug and its metabolite pass into human milk. Restricted Use

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes several clinically significant interaction patterns involving Clint (Allopurinol). These are classified primarily as pharmacokinetic interactions and pharmacodynamic risks, which necessitate specific restrictions and monitoring.


Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance Interaction Pattern & Restriction Classification
Mercaptopurine / Azathioprine Allopurinol inhibits metabolism, causing increased exposure; mandatory dose reduction (e.g., to 25% of usual dose) is required. Enzyme-Mediated
Pegloticase Co-administration is contraindicated and must be avoided. Contraindicated
Thiazide Diuretics Increased risk of hypersensitivity reactions, particularly in patients with decreased renal function. Pharmacodynamic
Uricosuric Agents (e.g., Probenecid) Increases the clearance of Oxypurinol (active metabolite), which can reduce the therapeutic effect. Exposure-Altering
Ampicillin / Amoxicillin Co-administration is associated with an increased frequency of skin rash. Pharmacodynamic

Administration and Timing Constraints

Antacids containing Aluminum Hydroxide may reduce the absorption of Allopurinol. Regulatory information advises that the administration of these antacids be separated in time from Clint to mitigate this reduction. The combined use of Allopurinol with other cytotoxic agents, such as Cyclophosphamide, may enhance bone marrow suppression, requiring caution. The combination with Ciclosporin can also result in increased plasma concentrations of Ciclosporin.

Mechanism of Action

Targeted Inhibition of Uric Acid Synthesis

This medicine works by engaging in targeted enzyme inhibition within the Purine Catabolism Pathway. Its active form, Oxypurinol, forms a tight, long-lasting complex with the enzyme Xanthine Oxidase (XO), the biological catalyst that converts precursor molecules into uric acid. This blockade results in systemic regulation of uric acid synthesis throughout the body.


Metabolic Re-routing and Precursor Management

By preventing the final step of the purine breakdown, the drug causes the body to shift its purine metabolism dynamics. The more soluble precursors, Hypoxanthine and Xanthine, accumulate and are either recycled via the Purine Salvage Pathway or are subject to increased renal excretion. This process creates a consistently low metabolic saturation state, influencing the solubility dynamics of Monosodium Urate (MSU) in the surrounding fluids. The increased excretion alters the distribution of purine catabolites and influences the overall purine metabolic equilibrium.

Dosage and Administration Information

The administration of Clint (Allopurinol) follows established guidelines detailing the approved route, dosage, and intake conditions. This medicine is available for administration by two approved routes: the oral tablet and the intravenous (IV) infusion form, with IV use typically reserved for patients who cannot tolerate oral intake.

Dosing and Schedule

The dosage schedule for chronic hyperuricemia usually begins at a low initial oral dose of 100 mg once daily. The dose is gradually increased through weekly titration until a stable maintenance dose, typically ranging from 200 mg to 600 mg daily, is reached. The maximum recommended daily oral dose is 800 mg. For consistency, daily doses exceeding 300 mg must be administered in divided doses to aid tolerability. If a dose is missed, the patient is advised not to double the next scheduled dose.

Administration Conditions

Specific instructions for intake are required. Oral tablets are generally better tolerated and should be taken following meals. Furthermore, patients must ensure high fluid intake to promote adequate daily urinary output. Dosage adjustments are mandatory for certain patient populations; for instance, adult patients with documented renal impairment require a reduction in the standard daily dosage. The intravenous form requires reconstitution and dilution to a concentration that must not exceed 6 mg/mL prior to infusion.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Clint (Allopurinol)

The body of research for Clint consists of various clinical study designs, including randomized controlled trials and observational studies. This overview describes what the research has explored and what the studies describe, using language that avoids clinical recommendations or certainty about individual results.


Evidence for Chronic Management of Gout

Research exploring Clint's role in the long-term management of gout relies on numerous Randomized Controlled Trials (RCTs) and systematic reviews. These studies primarily focused on adult populations, including those with conditions such as chronic kidney disease (CKD).

Findings describe patterns observed in the studies where participants often achieved the achievement of a lowered serum uric acid (SUA) level. Some trials described patterns where the observed rate of acute gout flares differed over follow-up periods in groups that attained lower SUA levels versus those that did not. Initial research exploring the use of a urate-lowering agent has also documented that the early treatment period may temporarily be associated with an increased frequency of flares.

What remains uncertain: SUA reduction was observed in multiple types of studies, but long-term effects are not fully established for every patient subgroup. Research indicates that challenges such as dosing and patient adherence in real-world settings may be a source of outcome variability.


Evidence for Acute Support in Cancer Treatment

Research explored the use of Clint in the setting of rapid cell breakdown due to specific cancer therapies, often referred to as a strategy to manage Tumor Lysis Syndrome. This research was evaluated in comparative trials and retrospective observational data, focusing on preventing critical, short-term physiological imbalance.

The research examined acute outcomes, primarily the prevention of elevated serum uric acid concentration and the maintenance of markers of proper kidney function (like creatinine) during the immediate days surrounding chemotherapy administration. The study populations included both adult and pediatric patients with specific high-risk cancers.


Areas Where Research Remains Inconclusive or Limited

Scientific review consistently highlights several areas where the research evidence surrounding Clint is either inconsistent or incomplete:

  • Asymptomatic Hyperuricemia: The largest area of uncertainty is whether using Clint to lower high uric acid levels in people who do not have gout appears to affect the observed patterns in other chronic conditions, such as markers of renal function or cardiovascular events. Certainty remains low in this area due to conflicting results from multiple large-scale trials.
  • Comparative Evidence: For certain types of outcomes, such as changes in overall quality of life or function, comparative evidence is lacking or limited when comparing Clint against all modern urate-lowering drugs in rigorous head-to-head trials.

Frequently Asked Questions (FAQ)

Common questions about Clint (FAQ)

Q: What part of the body does Clint primarily target?

A: Clint works to regulate the levels of uric acid throughout the body. Official information states the drug's purpose is to inhibit a specific enzyme called xanthine oxidase. The drug targets this enzyme, which is necessary for uric acid production.

Q: What should a patient generally expect in the first week of taking Clint?

A: Regulatory information indicates that Clint should ideally be started after an acute gout attack has ended. During the early stages of treatment, some patients may notice an increase in gout attacks or flares. Any increase in flares is a matter to be addressed by a healthcare provider.

Q: How can I tell if Clint is actually working for me?

A: Clint is designed to lower the level of uric acid in your blood and urine. The effectiveness of the medication is typically assessed by monitoring serum uric acid (SUA) levels through lab tests, as requested by a healthcare provider.

Q: What happens to Clint in the body after it is swallowed?

A: After it is swallowed, Clint is rapidly processed by the body into its main active component, which is called oxipurinol. Official pharmacological studies show that this metabolite is primarily responsible for the drug's therapeutic effect and remains in the body for a long duration.

Q: What are the signs of an allergic reaction to Clint?

A: Official information states that a rash or other signs of hypersensitivity are events that require immediate medical attention. Severe allergic reactions mentioned in regulatory documents can also include fever, redness of the eyes, and shivering.

Q: Are there any specific foods I should avoid while on Clint?

A: Official patient information states there are no specific foods or drinks that must be avoided while taking Clint. The decision to limit consumption of high-purine foods, such as certain red meats or organ meats, is generally part of overall gout management.

Q: Where can I find the official prescribing information for Clint?

A: Official regulatory agencies, such as the FDA and EMA, publish detailed documents about Clint. These are referred to as the Full Prescribing Information or the Summary of Product Characteristics (SmPC), and a patient-facing document called the Patient Information Leaflet (PIL).

Q: Why is Clint only available by prescription?

A: Clint is classified as a prescription-only medicine because it requires medical guidance and monitoring. This is necessary for managing the dose and safely overseeing the patient's condition.

Q: What happens if Clint is stored improperly (e.g., in a humid place)?

A: Official guidance emphasizes that Clint should be kept in its original container at room temperature and protected from moisture and high heat. Improper storage can potentially lead to a reduction in the medication's intended effectiveness.

Q: Is Clint a generic or a brand-name medication?

A: The name Clint, which corresponds to the active ingredient allopurinol, is the generic name. Regulatory documents indicate that the drug is also sold under various brand names, such as Zyloprim® and Aloprim®.

Q: Are there other names that Clint is sold under?

A: Yes, the active ingredient in Clint (allopurinol) is sold under other common brand names. Regulatory sources list brand names such as Zyloprim and Aloprim.

Q: Is Clint a controlled substance?

A: Clint is designated as a prescription-only medicine that requires a healthcare provider's supervision. However, official sources do not classify it as a controlled substance like certain pain medications or sedatives.

Q: How fast does Clint start to work after the first use?

A: The process of reducing uric acid production can begin within 2 to 3 days of starting Clint. Full achievement of the desired therapeutic effect, however, is typically observed after 7 to 14 days of continuous use.

Q: How long does the effect of one dose of Clint typically last?

A: The drug's primary effect comes from its active metabolite, oxipurinol. Official pharmacokinetic information indicates this metabolite has a long duration of action, typically lasting 15 to 20 hours, which supports a once-daily dosing schedule.

Q: Does Clint cause weight gain or weight loss?

A: Weight changes are not listed among the most common adverse effects of Clint. However, official safety documentation notes that in rare cases, unexpected weight loss and loss of appetite have been reported.

Q: Is it normal to feel a little dizzy when first starting Clint?

A: Official safety information reports that both dizziness and drowsiness have occurred in patients taking Clint. Awareness of these possible effects is recommended during daily activities.

Q: Does Clint affect a person's mood or behavior?

A: Mood or behavioral changes are generally not common with Clint. However, official patient safety documents report rare occurrences of side effects, including agitation, confusion, or depression.

Q: Can Clint affect sleep patterns?

A: Sleep-related side effects have been reported in official product information. These effects can include both drowsiness (feeling sleepy) and sleeplessness (insomnia).

Q: Is it safe to drink alcohol while taking Clint?

A: Alcohol does not directly alter the way Clint works in the body. Official information notes that alcohol consumption may contribute to increased uric acid levels. Such increases are associated with a greater risk of gout flares.

Q: Is Clint suitable for people over the age of 65?

A: Yes, Clint is used in the older adult population. Dose adjustment is often considered, particularly for patients who have reduced kidney function.

Q: What restrictions on activity are mentioned in the Clint patient information?

A: Regulatory documents state that patients should use caution when performing hazardous tasks, such as driving or operating machinery, until they are aware of how the drug affects them, due to the risk of dizziness or drowsiness.

Q: Will Clint make me drowsy or affect my ability to concentrate?

A: Yes, regulatory safety documents list drowsiness and somnolence (sleepiness) as possible side effects. Due to these reported effects, caution is warranted before engaging in tasks requiring full mental focus.

Q: Does Clint have a risk of dependence or misuse?

A: Official drug classification confirms that Clint is not considered a controlled substance. Regulatory data does not indicate a risk of dependence or misuse associated with this drug.

Q: Does Clint contain lactose or gluten?

A: Regulatory documents listing the inactive ingredients (excipients) confirm that Clint tablets contain lactose monohydrate. Patients with certain hereditary intolerances to lactose should be aware of this. Information regarding gluten is generally not a required regulatory disclosure.

Q: What should I know about taking Clint before an upcoming surgery?

A: In general, Clint can often be continued without interruption during the time surrounding a surgical procedure. In cases of pre-existing kidney issues, there may be consideration by the patient's healthcare team to adjust or temporarily interrupt the dosage.

How should Clint be stored and disposed of?

Official Storage and Disposal Requirements for Clint

The required storage and disposal of Clint medication are strictly defined by regulatory standards (e.g., FDA, EMA) to maintain the product's stability and safety.

Storage Conditions

Requirement Official Regulatory Statement
Temperature Store at a controlled temperature range, typically Do not store above 30°C (or 86^circmathrmF).
Protection Keep the product in its original container and protect it from moisture and direct light.
Handling Do not freeze the medicine unless directed otherwise. Keep the bottle or container tightly closed at all times.

Disposal and Safety

Official labeling mandates that Clint must be kept out of the sight and reach of children to prevent accidental ingestion.

Unused or expired Clint should be disposed of through a dedicated drug take-back program or official collection site. Regulatory guidance advises against flushing the product down the toilet or placing it in household trash unless explicitly instructed otherwise by a national health authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Clint found in:

A-Z Index: